of bone matrix constituents, such as collagen and ground patients. Chronic renal failure is often associated with bone substances. Bone resorption depends on osteoclasts, disorders, including secondary hyperparathyroidism, alumiwhich are giant multinucleated cells that are usually num-related low-turnover bone disease, osteomalacia, adyfound in contact with calcified bone surfaces and within namic osteopathy, osteoporosis, and skeletal ␤2-microglobulin the lacuna resulting from its own resorptive activity. The amyloid deposits. In spite of the enormous progress made during the last few years in the search of noninvasive methods to combination of these two processes is defined as bone assess bone metabolism, the distinction between high-and lowremodeling [2]. Despite the fact that they occur along turnover bone diseases in these patients still frequently requires the bone surface at random and that bone formation invasive and/or costly procedures such as bone biopsy after only takes place where resorption of old bone has already double tetracycline labeling, scintigraphic-scan studies, computed tomography, and densitometry. This review is focused
extraskeletal calcifications [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . After renal transplantation, in addition to the persistence of one or several of the previously mentioned disorders, three histologi-Bone is a specialized connective tissue composed of cally and less characterized entities can also be observed: cells and an extracellular matrix that has the unique painful legs syndrome, avascular bone necrosis, and imability to become calcified, thereby forming, in conjuncmunosuppression-related bone disease (Table 1 ) [14] . tion with cartilage, the skeletal system [1] . Its metabolism is characterized by two opposed processes: formation To date, the only method of making a clear-cut distincand resorption. The formation depends on osteoblasts, tion between high, normal, and/or low bone remodeling which are bone lining cells responsible for the production in these patients relies on the static and dynamic histological analyses of the iliac bone biopsy after double tetracycline labeling [3, 12] . This histological diagnosis can be tion of bone biopsies has markedly decreased during the last decade, probably because of the difficulties in finding been proved that such a procedure is safe and free from receptors major complications, with the incidence of complications Prostaglandin E 2 Plasminogene activator factor (PAF) being lower than 0.7%, without death or permanent dis-Inhibitor of the plasminogene activator factor (PAF-I) abilities [20, 21] . Moreover, many of the studies men-Cathepsins tioned earlier in this article are also invasive or too ex-Integrins Nitric oxide pensive to be performed routinely. Thus, considerable efforts have been devoted to the development of reliable noninvasive methods to assess bone metabolism in uremic patients. trate-resistant acid phosphatase (TRAP) and/or some of Thus, for a long time, the biochemical diagnosis or the multiple products resulting from the degradation of the presumption of the histological type of renal osteotype I collagen. Other circulating molecules might also dystrophy has been essentially based on the plasma intact prove to be of potential interest in evaluating bone turnparathyroid hormone (iPTH) concentration because of over, namely, bone sialoprotein, ␤2-microglobulin, caits relative good correlation with bone histomorphomethepsins, nitric oxide, advanced oxidation protein prodtric parameters [22] [23] [24] [25] [26] . However, it is now obvious that ucts (AOPPs), advanced glycation end products (AGEs), the measurement of a single parameter such as plasma cytokines as interleukins (IL-1, IL-6, and IL-11), soluble iPTH does not provide sufficient information to make IL-6 receptor, tumor necrosis factor-␣ (TNF-␣), transa final diagnosis. First, the plasma iPTH concentration forming growth factor-␤ (TGF-␤), bone morphometric basically reflects the degree of activity of parathyroid glands. Second, given that the uremic state is often asso-proteins (BMBPs) and their soluble receptors, growth ciated with a resistance of bone cells to the actions of factors such as insulin growth factor-I (IGF-I), macro-PTH, the relationship between plasma iPTH levels and phage colony-stimulating factor (MCS-F), and granulobone formation rate (BFR) is not always maintained cyte-macrophage colony stimulating factor (GMCF-F; [27] [28] [29] . Since 1992, this has led to the assumption that tetrameric form. Then it is anchored to the outer surface of the cellular membrane to inositol phosphate by a glycan ester [48] . In vitro studies indicate that bAP activity is released from the osteoblastic surface in either of zyme-linked immunosorbent assay (ELISA) from Metra two forms: an anchorless, soluble (hydrophylic) form Biosystems, Inc. (Palo Alto, CA, USA), which measures and an anchor-intact, insoluble (hydrophobic) form [51] .
the activity, correlate well with the values obtained by Most of the bAP that appears in human serum is essenseparation methods such as Isopal from Beckman (Palo tially in the anchorless or soluble form. Its plasma con-Alto, CA, USA) [65] . It has been suggested, however, centration depends on the rate of release from osteothat the electrophoretic method is more sensitive than blasts and the rate of hepatic degradation [52] .
the other methods when measuring low concentrations Bone AP is a robust molecule because most of its of bAP [65, 66] . activity is still found after 72 hours at 4ЊC, after several As expected, using these new methods, recent obseryears stocked at Ϫ 20ЊC, and after several cycles of freezvations have shown that plasma bAP is more sensitive ing and thawing. The physiological role of bAP is yet to than total alkaline phosphatases (tAP), OC, and osbe fully understood. However, bAP seems to be essential teonectin in the evaluation of bone remodeling in chronic for the process of mineralization and bone formation.
renal patients [27, 29, [67] [68] [69] [70] [71] . Furthermore, because the It catalyzes the hydrolysis of phosphate ester, thereby monoclonal antibody against bAP exhibits a low crossenhancing the mineralization by hydrolysis of pyrophosreactivity with other alkaline phosphatases, it has bephate, which is an important inhibitor of mineralization, come possible to differentiate the elevation of tAP seen and by providing a high phosphate concentration at the in liver diseases from that caused by osteopathies [56, osteoblastic surface [46, 53] . Moreover, molecular exper-65, 72-77]. iments showed that the transfection of its cDNA confers During life, there are two age-dependent physiological the capacity of mineralization to cells normally lacking peaks of plasma bAP, one during infancy and the other the alkaline phosphatase gene [50] . Likewise, alkaline during puberty. Both peaks are disturbed in pediatric phosphatases may be important in the vitamin B metabouremic patients in accordance with their altered longitulism. Transgenic mice in which the AP gene has been dinal growth [78] . Nonetheless, in such children, plasma knocked out by homologous recombination die of sei-bAP correlated with iPTH and not with tAP and showed zures and vitamin B6 deficiency [54] . a better correlation with height velocity than tAP. Plasma Different methods have been employed in order to bAP correlates also with bone trabecular density, the measure plasma AP isoforms, such as heat denaturation, metabolically most active part of bone, pointing to its chemical activators or inhibitors of specific AP isoensignificance as a marker of bone formation [77]. zymes, wheat germ lectin or concanavalin A precipita-In adult hemodialysis patients, values of plasma bAP tion, eventually followed by separation by agarose gel higher than 20 ng/ml are constantly associated either electrophoresis or by high-performance affinity chromawith biological and histological signs of secondary hypertography [55] [56] [57] [58] [59] . However, these methods are expenparathyroidism or with high bone turnover (Table 3 ) sive, laborious, time consuming, and of insufficient sensi- [27] . In addition, plasma bAP correlates well with iPTH. tivity to be easily and reliably applied in clinical practice.
Such correlation is better than that of tAP with iPTH Fortunately, specific monoclonal antibodies against bAP ( Fig. 1 ). Plasma bAP also correlated better than iPTH have been successfully developed and used in radioimand tAP with most bone histomorphometric parameters, munological and immunoenzymatic assays [60] [61] [62] [63] [64] . The including osteoclast and osteoblast surfaces [29] . Accordvalues obtained using immunological assays such as Osingly, when based on these bone parameters, the sensitivtase, IRMA from Hybritech (San Diego, CA, USA), which measures the mass of bAP, and Alkaphase, en-ity and specificity of a bAP of more than 20 ng/ml can reach 100% in the prediction of a high bone turnover patients have both bAP and iPTH within normal ranges.
In the zone of high values, there is a great variability. disease and a positive predictive value of 84% [29]. This does not seem to be the case in the absence of bone For example, for comparable plasma bAP levels of 60 to 80 ng/ml, some patients have iPTH values of 500 biopsy evidence. If the diagnosis of secondary hyperparathyroidism is made on the basis of a iPTH of more than to 600 pg/ml and others 1000 to 1100 pg/ml, probably reflecting different degrees of skeletal response to PTH. 200 pg/ml and a bAP of more than 20 ng/ml, then the sensitivity of bAP decreases to 56% and the specificity Forty-five to 50% of them have either low or high bAP and iPTH. Twenty-five to 30% of the patients have in-to 92%, probably because a lot of patients have iPTH values higher than 200 pg/ml without elevated bAP. Its creased plasma iPTH levels above 200 pg/ml and normal bAP. Less frequently observed, 10 to 15% of the patients high specificity suggests, however, that a plasma bAP higher than 20 ng/ml formally excludes the existence of have increased plasma bAP levels and normal iPTH ( In the cases of high plasma bAP associated with plasma iPTH levels, which are either low or within the In contrast, to give a plasma bAP value below which there would be a great probability of having an adynamic limits considered as normal in such patients (less than 200 pg/ml) [30], several hypotheses have been presented or low-turnover bone disease appears to be more difficult. The two bone biopsy-based studies reported so far to explain this phenomenon. First, the cut-off value of 20 ng/ml might be inadequate in the presence of a con-employed different and noncomparable methods of bAP measurements [29, 66] . On the other hand, the low num-comitant increase of tAP. As reported earlier in this article, the antibodies against bAP show a cross-reactiv-ber of adynamic bone disease (ABD) patients in one of the studies did not allow us to obtain a sensitive plasma ity of only 16% with tAP. However, it has been demonstrated that its radioimmunological measurement can bAP concentration predictive of ABD. However, from these observations, it can be proposed that the diagnosis still be considered reliable if the elevation of tAP does not exceed 2.6 times the upper normal limit [62] . Second, of ABD in hemodialysis patients should be suspected when plasma iPTH levels are less than 150 pg/ml and as the liver, kidney, and bone AP isoenzymes are encoded by the same gene, there could be an extraskeletal that bAP levels are lower than 7 ng/ml (Ostase) or 27 U/ liter (Isopal) [29, 66] . A recent study in 41 hemodialysis synthesis of bAP, either hepatic or renal. It is known that liver cells of dialysis patients are often abnormally patients who underwent a bone biopsy demonstrated that a plasma bAP concentration lower than 12.9 ng/ml activated by virus contamination [49, 81, 82] . Third, the production of skeletal bAP could be independent of the had a sensitivity of 100%, a specificity of 94%, and a positive predictive value of 72% in the prediction of a PTH-stimulated osteoblastic activity. Several cytokines and growth factors have been shown to exert a PTH-low bone turnover [80] .
The correlation between plasma bAP and iPTH shown like action on bone cells. Among them, IL-1, IL-6, and TNF are usually found increased in the plasma of hemo-in Figure 1 illustrates how difficult it is to separately interpret either of the values. Only 15 to 20% of the dialysis patients [37, 83] . Fourth, the serum concentration of certain electrolytes could influence the concentration bone resorption appears to predominate over bone formation, as evidenced by the bone loss observed during of bAP. It has been demonstrated that bAP activity is proportional to the concentration of phosphate in the the first year following a kidney graft. Unfortunately, our understanding of bone metabolism during kidney culture milieu [84] . The release of bAP activity into the circulation can be negatively regulated by calcium [51] .
transplantation is limited, as few studies with bone histomorphometrical data have been performed so far. Likewise, an inverse relationship between plasma urea concentration and bAP activity has been observed in the In most cases, the response to medical treatment in uremic patients with secondary hyperparathyroidism rat [85] . Finally, the association of high bAP with low iPTH levels might surprisingly indicate the sign of a such as oral or intravenous calcitriol has been based on the diminution of plasma iPTH levels alone. However, certain degree of skeletal aluminum overload [86] .
The finding of low plasma bAP concentrations with it has been noted that calcitriol can have a direct effect on bone turnover independent of its effect on PTH synthesis iPTH levels higher than 200 pg/ml in 15 to 20% of hemodialysis patients may have several explanations. First, [68] . Calcitriol decreases the expression of PTH receptors on osteoblasts and, thereby, the action of PTH on this strongly suggests that an increased plasma iPTH is not always indicative of high bone turnover in these bone remodeling. Such an effect could lead to the initiation of a low bone turnover bone disease even in the patients. Second, a low plasma bAP level probably reflects reduced bAP synthesis by uremic osteoblasts. It has presence of relatively high plasma iPTH levels [9, 68, 91]. We have observed that plasma bAP levels can help been shown that cultured osteoblasts from hemodialysis patients respond less well to several stimuli, including in making a decision to lower the dose or to stop calcitriol altogether [68] . PTH, than those from normal individuals [87] . Third, the poor response of osteoblasts to PTH and the low In summary, all of the observations described earlier in this review suggest that in the absence of bone histology, plasma bAP may result from down-regulation of PTH receptors in these uremic cells [28] . Fourth, the presence plasma bAP alone provides useful information about the of a genetic alkaline hypophosphatasemia could be rerate of bone remodeling in hemodialysis patients. Its sponsible of the low plasma bAP levels as well [82, 88] .
combination with plasma iPTH improves the sensitivity, Finally, there is the possibility that no direct correlation the specificity, and the predictive value in the diagnosis exists between plasma bAP and iPTH on the ground of the type of bone turnover. When there is a dissociation that immunoassays overestimate the concentration of between both parameters, the sensitivity of bAP is higher the active form of iPTH. It has recently been demonthan that of iPTH, and it is, therefore, a better indicator strated that a non-(1-84) molecule of PTH that accumuof bone remodeling. Nevertheless, thus far, bone histolates in the serum of uremic patients can interfere with morphometry appears to be still indispensable in making the measurement of iPTH by currently used methods the distinction between patients with normal bone and [31, 32, 89].
patients with adynamic bone disease and in situations in We cannot exclude that the dissociation between bAP which there is a discordance between plasma bAP and and iPTH could also reflect an uncoupling between bone iPTH values. Again, it should be stressed that an indeformation and bone resorption. In this regard, on the pendent augmentation of either plasma iPTH or bAP basis of bone histomorphometry, some patients have no may not always correspond to an increased bone turntetracycline double-labeled bone formation surfaces and over. maintained bone resorption (unpublished personal re-
The idea that in hemodialysis patients one must try sults).
to maintain plasma iPTH levels three to four times higher After surgical parathyroidectomy (PTX), the plasma than the normal values should not be taken as a general bAP concentration behaves like iPTH, decreasing from rule, with each patient requiring an individual evaluaan approximate mean value of 40 ng/ml before PTX to tion. As described before, paradoxically, histomorpho-10 ng/ml three months after PTX. . ␥ Carboxylation octo 90% of patients. Plasma OC levels decrease with the curs principally at glutamine residues 17, 21, and 24 and normalization of renal function. Paradoxically, plasma depends on the presence of the cofactor vitamin K. Car-bAP levels show a tendency to increase, probably beboxylation of the glutamic acid at position 17 seems to cause of the augmentation of bone turnover induced by most of the immunosuppressive drugs [14, 71]. However, be essential for the structural and spatial conformation of the molecule allowing the interaction with hydroxyap-osteocalcin might actually be an inhibitor of bone formation. The synthesis of osteocalcin by mature osteoblastic atite crystals [95, 96] . When there is a deficiency in vitamin Ks (K1 or phylloquinone and K2 or menaquinones:
cells is probably one of the signals used by PTH to slow osteoblastic activity and thereby bone formation [105-MK-4, MK-7, and MK-8), the carboxylate fraction of OC tends to decrease and can be associated with a re-108]. Numerous studies have shown the degree of interest duced bone mass and a high risk of fractures (abstract; Nakazawa et al, Nephrol Dial Transplant 13: A43, 1998) in the use of plasma osteocalcin measurements in several metabolic bone diseases [61, [109] [110] [111] [112] . It has always been [97] [98] [99] [100] . Indeed, intestinal absorption of vitamin K is in part regulated by apolipoprotein E (apoE). Recently, considered to be a useful marker of the rate of bone formation. However, its use in the context of renal osteo-an association has been demonstrated between the level of plasma vitamin K and bone density, and the risk of dystrophy is still hampered by several problems. First, many osteocalcin fragments of yet unknown function are fractures in hemodialysis patients and in postmenopausal women having the polymorphism E4 in the apoE gene retained in the plasma of uremic patients. Second, at least three forms of intact osteocalcin can be measured [96, 100, 101 ]. In addition, another recent study has suggested the possibility that a deficiency in the menaqui-in the plasma: total, carboxylated, and decarboxylated. Third, the intact molecule is rapidly degraded at room none MK-7 could be one of the risk factors predisposing to adynamic bone disease in hemodialysis patients (ab-temperature. Thus, the concentration measured depends on the characteristics of the antibodies used in the assay. stract; ibid). The physiological explanation of this is probably that the incorporation of vitamin K-charged Many of these antibodies recognize the intact molecule but also some of the fragments. As already mentioned, lipoproteins into intestinal, hepatic, and bone cells depends exclusively on the attachment of apoE to its spe-osteocalcin fragments are also liberated during bone matrix degradation. It is possible that in the future there cific receptor. In the presence of the apoE4 phenotype, the incorporation of vitamin K seems to be reduced could be one or more of these fragments measurable in the plasma that is specific for bone resorption [98, [100] .
Human osteocalcin possesses 49 amino acids and is [113] [114] [115] . Finally, perhaps because of the limitations previously described, there is a great intra-analysis variabil-produced by only osteoblasts and odontoblasts under the control of 1,25-OH 2 D 3 . Incidentally, it was on the ity in the dosage of OC with most of the current assays Using the ELSA-OSTEO IRMA kit (Cis Bio Int.), which uses two antibodies, one recognizing the end of intact osteocalcin in the circulation is approximately five minutes [95] .
N-terminal fragment and the other recognizing a midregion amino acid sequence, we and others have shown The physiological role of osteocalcin is still not completely understood. Osteocalcin surely plays an impor-osteocalcin values four to six Z-scores higher in hemodialysis patients than in normal individuals [15, 61, 119, tant role in bone formation, perhaps favoring or preventing it. It was generally thought that osteocalcin 120]. In spite of this accumulation, the plasma osteocalcin concentration demonstrated good sensitivity in making stimulates bone formation, although recent studies have shown an impressive augmentation of bone formation the distinction between patients with hyperparathyroidism and those with normal or low bone turnover. The and bone density in transgenic animals lacking its gene. This has therefore led to the provoking hypothesis that values were 555 versus 198 ng/ml, respectively (Table 3 ) [119]. As with other biochemical markers, diagnostic sen-closure, and oxidation of one hydrolysine and two hydrolysine-derived aldehyde molecules, and DPD [lysylpyri-sitivity was low when the aim was to differentiate patients with adynamic bone disease from those with normal dinium (LP)] is formed from one lysine and two hydrolysine-derived aldehydes (Fig. 3) [124, 129, 130] . To date, bone turnover [15, 61] . Although weaker than bAP and iPTH, the correlations of plasma osteocalcin with bone only these two main collagen intermolecular cross-link molecules have been thoroughly studied; however, an-histomorphometric parameters in hemodialysis patients were quite good [27, 29, 119] .
other kind of intramolecular cross-link, which is formed from the condensation of two aldehyde groups and The results of these studies demonstrate the limitation of the use of plasma osteocalcin as a biochemical marker serves to joint the ␣1 chains of the same collagen molecule, has also been described [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] . of bone remodeling in patients with impaired renal function and in patients under hemodialysis treatment. Obvi-Both PYD and DPD are present in bone and cartilage, although most of the pyridinium cross-links found in the ously, a clear understanding of the physiological role of cartilage are in the form of PYD, in contrast with DPD, osteocalcin and its fragments is still lacking. The developwhich is predominantly in bone [123, 124, 133] . Metaboliment of new assays will certainly increase its sensitivity cally, these molecules are nonreducible and cannot be in the evaluation of renal osteodystrophy [121, 122] .
reused during new collagen synthesis (abstract; Robins et al, J Bone Miner Res 6:C642, 1991) [134] . Furthermore, PYRIDINOLINES diet-derived cross-link molecules are not absorbed from Eighty-five to 90 percent of bone matrix consists of the intestine [134] . Following bone resorption and bone type I collagen (Fig. 2) [123] [124] [125] . It is this molecule collagen degradation by specific osteoclast-related enthat mostly provides the mechanical force of bone tissue zymes, PYD and DPD are released into the circulation, because of its particular intramolecular and intermolecuand because of their low molecular weight (429 to 591 lar cross-links, which are responsible for the tensile Da), they are normally excreted into the urine, as much strength of collagen fibers [125] . Mutations in the gene as 40% in their free forms [124, [135] [136] [137] [138] . Usually, serum of type I collagen ␣1 chain have been associated with low levels of PYD and DPD are extremely low and undetectbone density and osteoporosis [126] . The mechanisms able in normal individuals; therefore, their measurement leading to the formation of these cross-links are still is commonly performed in urines. The renal clearance poorly understood, although several biochemical prois different for free and conjugated forms. The fractional cesses have been described. First, lysine residues located clearance of free forms is higher than one, suggesting at specific regions in the type I collagen ␣1-chain (amino tubular secretion, whereas the fractional clearance of the acids 103 and 1043) are hydroxylated ( Fig. 3) [124] [125] [126] [127] [128] .
conjugated forms is less than one [139] . Based on these Then, in presence of copper, the enzyme lysyloxidase properties, it has been suggested that quantitative analydeaminates hydroxylated lysine residues giving rise to sis of PYD and DPD in the serum as well as in the aldehyde groups. It is thought that PYD [hydroxylysylurine could provide valuable information about bone resorption rate. pyridinium (HP)] is formed from the condensation, ring 
. Schematic representation of two major collagen cross-linking molecules pyridinoline (PYD) and deoxypyridinoline (DPD).
AA means the amino acid number at which PYD molecule attaches to amino-and carboxy-terminal ends of type I collagen molecules.
In the last two decades, intense research has focused
Fortunately, specific polyclonal and monoclonal antibodies have recently been successfully developed for the on the development of methods capable of accurately assessing urinary and plasma concentrations of PYD and direct measurement of PYD and DPD (abstract; Robins et al, ibid) [142, 143] . The concentrations of PYD and DPD, as well those found in a diversity of tissues including bone, cartilage, tendon, dentin, skin, cornea, and DPD measured by ELISA methods are usually 4 to 10 times lower than the value obtained by HPLC [137, 142] . vessels. The first methods were based on conventional chromatography after borohydride reduction of collagen Nevertheless, the values obtained with either method are excellently correlated (r ϭ 0.85 to 0.90). In addition, cross-links, high-performance liquid chromatography (HPLC) using aminopropyl-silica column and radioac-some authors have even reported that the measurement of DPD by ELISA is more reliable than by HPLC [136, tivity monitoring, followed by HPLC and fluorescence detection techniques. Last, reproducible results have 137, 142, 143] . Moreover, measurement of PYD and DPD, released after hydrolysis of the urine sample, been obtained using reversed-phase, ion-pair quantitative HPLC (abstract; Robins et al, ibid) [124, [136] [137] [138] [139] [140] [141] .
either by HPLC or ELISA (Table 4) , has been shown to serve as an excellent marker of bone resorption rate Certainly, HPLC-based techniques are highly quantitative and reliable; however, they are too time consuming in malnourished children, osteoporotic and postmenopausal women, primary and secondary hyperparathy-and cumbersome to become a routine clinical application.
roidism, rheumatoid arthritis and osteoarthritis, Paget's [93, 119, 134-137, severe renal failure. In a study dealing with patients treated by hemodialysis and peritoneal dialysis, the au-140-150]. In addition, an Italian group has recently demonstrated the increase in urinary excretion of PYD and thors observed that circulating PYD and DPD levels were 50 to 100 times higher than in controls, decreased DPD in normocalcemic patients with kidney transplantation was more sensitive than plasma measurement of postdialysis, and could be measured in the dialysate [149] . iPTH, bAP, and tAP for the diagnosis of secondary hyperparathyroidism [150] . In another study dealing with Recently, using a competitive enzyme immunoassay for the measurement of PYD in the serum (Metra Bio-patients treated by peritoneal dialysis, PYD and DPD concentrations in serum, urine, and dialysis fluid were systems), it has been found that serum levels of PYD were significantly increased in osteoporotic women, pa-well correlated with plasma iPTH and bAP levels. Moreover, the authors observed that circulating PYD and tients with hyperthyroidism, and patients with primary hyperparathyroidism [152] . With this ELISA, we as-DPD levels progressively increased with the duration of renal failure and with the time spent on peritoneal dial-sessed serum-free PYD levels in a group of 37 uremic patients undergoing hemodialysis. We found that these ysis [149] .
Few studies have been performed concerning the me-patients had markedly increased (10-to 30-fold) serum PYD levels compared with normal individuals (Table 3 ) tabolism of PYD and DPD in uremic patients with or without bone diseases. Two recent observations have [119] . High serum PYD levels were generally associated with high turnover bone disease and were positively cor-suggested that urinary cross-link excretion was unaffected by renal dysfunction [142, 151] . However, none related with bone resorption and bone formation parameters. These correlations were comparable to those of the patients included in these two studies had advanced renal failure (creatinine clearance below 10 ml/ found between serum bAP and bone histomorphometric parameters. However, serum PYD was correlated sig-However, few studies have been performed in uremic patients. A decade ago, a correlation between serum nificantly better with bone histology than either serum iPTH or osteocalcin [119] . No difference was observed TRAP and bAP levels was demonstrated using electrophoretic methods [155] . Another group, using an enzy-in serum PYD levels between patients dialyzed on highflux or standard cellulosic dialysis membrane, which may matic method, has recently shown a correlation between serum TRAP activity and the number of osteoclasts and indicate that the type of dialysis membrane would not have a major influence on serum PYD levels. In a recent the percentage of eroded bone surface (abstract; Malluche et al, J Am Soc Nephrol 2:337, 1991). Similarly, study, using a commercial radioimmunoassay from Nichols, it has been observed that serum DPD levels higher serum TRAP appears to correlate with plasma tAP and iPTH [164] [165] [166] [167] . than 21 nmol/liter had a sensitivity of 88% and a specificity of 93% in the diagnosis of a high remodeling Specific antibodies against TRAP have been successfully developed and applied in an ELISA [154, 168] . disease [81] .
From these studies, it can be argued that serum PYD With this method, elevated levels of TRAP have been found in the serum of patients with primary hyperpara-and DPD may be useful biochemical markers of bone resorption in chronic renal patients. It seems that the thyroidism. Surprisingly, however, it was found that normal subjects had measurable amounts of serum TRAP sensitivity and specificity of these markers are greater in cases of increased bone remodeling. Hopefully, more [154] . It is likely, therefore, that the specificity of this ELISA assay may not be perfect, in that it might be sensible measurements of collagen cross-linked molecules will be developed and will become common tests recognizing other acid phosphatases or the same TRAP produced by other cells. Significant TRAP activity has in clinical practice.
recently been detected in osteoblasts and osteocytes [154] .
TARTRATE-RESISTANT ACID PHOSPHATASES
To date, the value of serum TRAP measurement in Acid phosphatases are lysosomal enzymes produced uremic hemodialysis patients still remains to be estabby osteoclasts, prostate, uterus, pancreas, spleen, blood lished. The sensitivity of enzymatic methods and the few red and white cells, and platelets. Analogous to tAPs, available immunological assays are still low. Certainly, the different acid phosphatases can be identified and progress in understanding its physiological role as well measured by enzymatic, electrophoretical, or chromatoas its biochemistry and immunochemistry should lead to graphic methods [152] [153] [154] [155] . Thus, the bone-specific acid the development of more sensitive assays [168] . phosphatase (TRAP), or the purple acid phosphatase because of its iron content, has been proposed as a poten-PROCOLLAGEN TYPE I CARBOXY-TERMINAL tial marker of bone resorption. TRAP has a molecular EXTENSION PEPTIDE weight of 30 kDa but circulates in the serum as a 250 kDa complex, which also contains calcium [152] . Serum Type I procollagen carboxy-terminal extension peptide (PICP) results from the extracellular cleavage of a TRAP had previously been determined by virtue of its resistance to tartric acid. However, many questions have molecule of type I procollagen at the moment of its incorporation into the bone matrix (Fig. 2) [169, 170] . been raised about its osteoclast specificity. Moreover, even though TRAP appears to be essential to the process PICP has a molecular weight of approximately 100,000 Da. Its plasma concentration is not altered by renal fail-of bone resorption, its physiological role on the skeleton is yet ill understood. It is known that TRAP dephosphor-ure because its degradation takes place in the liver through the mannose-6-phosphate receptor. Specific an-ylates a variety of bone matrix proteins such as osteopontin and sialoprotein [156] . In addition, transgenic mice tibodies against PICP have been developed and are actually employed to measure its plasma concentration [119, with targeted disruption of the TRAP gene develop an osteopetrotic phenotype with altered osteoclastic func- [169] [170] [171] [172] [173] [174] [175] [176] . Because PICP is produced by osteoblasts during the process of bone formation, plasma PICP concen-tion [157] . In spite of these transgenic studies, little is known about the TRAP gene [158, 159] . It belongs to a tration has been proposed as a biochemical marker of bone formation. family of genes that codes for iron transport proteins in the placenta. Accordingly, the TRAP gene seems to be Nondialyzed patients with chronic renal failure have significantly increased plasma PICP levels [171] . How-regulated at the transcriptional level by extracellular iron concentrations. It possesses an iron-sensitive DNA se-ever, this increase does not correlate with other humoral markers of bone turnover or with bone histomorphome-quence (iron-response element) on its 5Ј untranslated region [160] . trical parameters. In the same study, it was observed that patients receiving 1,25OH 2 D 3 had higher plasma PICP In some studies, the amount and the activity of TRAP seems to correlate with bone resorption rate (abstract; levels than patients without treatment. tory. Some workers have found that plasma PICP con-loid deposits in osteoarticular tissues [183] . In addition centration provides useful information regarding the to being an indicator of an inflammatory state, it has degree of bone formation. They also observed that PICP been suggested that ␤ 2 m could serve as a bone remodellevels correlate quite well with plasma bAP, osteocalcin, ing marker as well [184] . Serum ␤ 2 m concentrations have iPTH, and bone formation rate (BFR) [169] .
been found to correlate with serum TRAP in postmeno-By analogy with plasma bAP, PICP levels increased pausal women [185, 186] . Moreover, in a recent study, significantly during the first two weeks after surgical we have observed that patients with severe secondary PTX, probably as a consequence of diminished osteoclast hyperparathyroidism showed significantly higher serum activity following the reduction of iPTH levels and an ␤ 2 m levels than patients with normal bone turnover. In increase in mineral deposition [119, 173, 177] . However, addition, serum ␤ 2 m correlated with serum bAP, PYD, our own observations have not demonstrated any great and osteocalcin levels [183] . value of plasma PICP in the diagnosis of the type of Regarding AGEs, these also have a tendency to accubone remodeling in hemodialysis patients [29, 119, 170, mulate in the serum of uremic patients. Recent studies 177]. Additional studies remain to be performed in order have shown that AGEs were able to stimulate bone to define its value in renal osteodystrophy.
resorption probably through the stimulation of IL-6 production [35, 187] . Because IL-6 is one important media-
PROCOLLAGEN TYPE I CROSS-LINKED tor of the action of PTH on bone cells [188], it is possible CARBOXY-TERMINAL TELOPEPTIDE
that AGEs could influence bone metabolism in hemodi-Telopeptides are small amino acid sequences originatalysis patients. Finally, bone sialoprotein, a glycoprotein ing from the nonhelical ends of collagen molecules. For of the bone matrix with a molecular weight of 70 to 80 instance, procollagen type I cross-linked carboxy-termi-kDa, has been shown to be a bone indicator of bone nal telopeptide (ICTP) is a part of type I collagen resorption in cancer patients and in menopausal women released during bone resorption and containing cross- [189] . linking molecules (Fig. 2) . One molecule of ICTP is composed of two C-terminal fragments from the ␣1 chain of CONCLUSIONS type I collagen, one helical segment from the ␣1 or ␣2 chain of collagen, and a cross-linker (PYD or DPD). Its
In the absence of bone biopsy information, it seems molecular weight is approximately 9,000 Da [178] . ICTP that there is no ideal marker of bone remodeling in is released into the circulation after the degradation of uremic patients. The time has come to regard the plasma several mature collagen molecules of the bone matrix iPTH concentration as the marker of parathyroid activity [125, 169, 170] . Therefore, plasma ICTP levels should and not as the indicator of bone turnover. As mentioned reflect the degree of bone resorption. before, increased plasma iPTH levels are not always These assays of plasma ICTP use polyclonal antibodies synonymous with high turnover bone disease and vice against a small group of cross-linked peptides of the versa. Among the biochemical markers of bone remodelhuman type I collagen [179] or against a group of eight ing revised herein, plasma bAP concentration appears to amino acids (EKAHDGGR) that correspond to the be more sensitive than iPTH, osteocalcin, TRAP, PYD, C-telopeptide domain of the ␣1 chain of type I collagen PICP, and ICTP in distinguishing the type of bone 
